Companies / AVE

AVECHO BIOTECHNOLOGY LIMITED

ASX:AVEPharmaceuticals, Biotechnology & Life Sciences
3.86B shares on issueASX (delayed) · as of 28 July 2026$0.021price · delayed$81.1Mmarket cap · indicative
B
Dilution grade

Share count grew 22% in 24 months; runway 4–8 quarters; 2 cash raises in 24 months

Cash runway5.3 quarters of funding
Share-count growth (24m)21.8%
Raise cadence (24m)2 cash raises
Options & rights overhang3.1% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

AVECHO BIOTECHNOLOGY LIMITED's ordinary share count increased 21.8% between April 2025 and June 2026, to 3.86B shares. The company raised capital twice in the 24‑month window for total proceeds of A$5.0M, most recently a A$2.5M placement in October 2025. Options and rights on issue could convert into 120M new shares, equal to 3.1% of the current share count, with 0% in the money at the current share price. At the March 2026 quarter the company reported A$5.1M in cash, representing 5.3 quarters of cover at its reported burn rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
3.1%
Max option dilution
0.0%
ITM option dilution
2
Raises · last 12 months
5.3 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 3.86B per ASX (delayed) (28 July 2026).
3.32B3.52B3.72BDec 24Sept 25July 26Cash raise · 23 Oct 2025Cash raise · 22 Oct 2025

Cash runway

5.3 qtrs
More than four quarters of funding at the recent spend rate.
$5.1M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
30 June 20262A · quoted issueAVE : ORDINARY FULLY PAID3.86BAppendix 2A
2 June 20263G · unquotedORDINARY FULLY PAID3.83BAppendix 3G
31 May 20263H · cancellationORDINARY FULLY PAID3.83BAppendix 3H
13 May 20262A · quoted issueAVE : ORDINARY FULLY PAID3.83BAppendix 2A
7 May 20262A · quoted issueAVE : ORDINARY FULLY PAID3.68BAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

2 cash raises in the last 24 months · 2 in the last 12 months

$2.5M
Placement
23 Oct 2025 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

3.1%
Total overhang · of current shares
0.0%
In the money · at current price
119.7M
Potential new shares
—
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
10 May 2026Matthew Patrick McNamaraSell—2.5M—3Y notice
10 May 2026Ross MurdochSell—2.5M—3Y notice
6 May 2026Gregory CollierOther800k——3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

30 June 2026Application for quotation of securities - AVE
23 June 2026Positive Phase III Interim Analysis Results Investor Webinar
23 June 2026$PPositive interim results from Phase III insomnia program
22 June 2026Phase III Interim Analysis Outcome Webinar
21 June 2026$PTrading Halt
2 June 2026Notification regarding unquoted securities - AVE
31 May 2026Notification of cessation of securities - AVE
31 May 2026Final Director's Interest Notice
26 May 2026Small Holding Share Sale Facility
26 May 20262026 Annual General Meeting Results
26 May 2026Chair's Address and CEO Presentation
25 May 2026Resignation of Non-Executive Director
25 May 2026Investor Webinar Presentation
21 May 2026$PReceipt of Research & Development Tax Incentive
21 May 2026$PAvecho completes treatment for Phase III interim analysis
13 May 2026Change of Director's Interest Notice x3
13 May 2026Application for quotation of securities - AVE
12 May 2026$PExpiry of Listed Options
7 May 2026Application for quotation of securities - AVE
1 May 2026Change of Company Secretary

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.